5.35
price up icon1.52%   0.08
after-market Handel nachbörslich: 5.39 0.04 +0.75%
loading
Schlusskurs vom Vortag:
$5.27
Offen:
$5.275
24-Stunden-Volumen:
522.70K
Relative Volume:
0.24
Marktkapitalisierung:
$293.98M
Einnahmen:
$3.64M
Nettoeinkommen (Verlust:
$-87.37M
KGV:
-1.3017
EPS:
-4.11
Netto-Cashflow:
$-86.46M
1W Leistung:
+1.90%
1M Leistung:
+15.80%
6M Leistung:
-4.29%
1J Leistung:
+49.03%
1-Tages-Spanne:
Value
$5.265
$5.40
1-Wochen-Bereich:
Value
$4.86
$5.57
52-Wochen-Spanne:
Value
$2.10
$9.10

Verastem Inc Stock (VSTM) Company Profile

Name
Firmenname
Verastem Inc
Name
Telefon
(781) 292-4200
Name
Adresse
117 KENDRICK STREET, NEEDHAM, MA
Name
Mitarbeiter
78
Name
Nächster Verdiensttermin
2024-11-06
Name
Neueste SEC-Einreichungen
Name
VSTM's Discussions on Twitter

Vergleichen Sie VSTM mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
VSTM
Verastem Inc
5.35 289.58M 3.64M -87.37M -86.46M -4.11
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
476.95 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
572.39 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.64 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
575.42 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
294.83 31.99B 3.81B -644.79M -669.77M -6.24

Verastem Inc Stock (VSTM) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-04-10 Eingeleitet Jefferies Buy
2025-03-24 Bestätigt H.C. Wainwright Buy
2024-12-31 Bestätigt BTIG Research Buy
2024-09-30 Eingeleitet Guggenheim Buy
2023-11-21 Fortgesetzt BTIG Research Buy
2023-09-27 Eingeleitet B. Riley Securities Buy
2023-06-15 Hochstufung Mizuho Neutral → Buy
2022-09-07 Fortgesetzt Alliance Global Partners Buy
2022-04-29 Fortgesetzt Cantor Fitzgerald Overweight
2022-04-14 Eingeleitet RBC Capital Mkts Outperform
2022-03-09 Eingeleitet Truist Buy
2021-07-01 Eingeleitet Alliance Global Partners Buy
2021-05-24 Hochstufung BTIG Research Neutral → Buy
2019-06-20 Herabstufung BTIG Research Buy → Neutral
2019-05-10 Herabstufung Raymond James Outperform → Mkt Perform
2018-07-13 Eingeleitet BTIG Research Buy
2018-05-02 Eingeleitet Seaport Global Securities Buy
2018-03-08 Eingeleitet B. Riley FBR, Inc. Buy
2017-09-07 Bestätigt H.C. Wainwright Buy
2017-04-13 Eingeleitet Oppenheimer Outperform
2017-03-24 Bestätigt H.C. Wainwright Buy
2015-09-29 Herabstufung Cantor Fitzgerald Buy → Hold
2015-09-29 Herabstufung JMP Securities Mkt Outperform → Mkt Perform
2015-09-29 Herabstufung Jefferies Buy → Hold
2015-09-29 Herabstufung Raymond James Strong Buy → Outperform
2015-09-28 Herabstufung Mizuho Buy → Neutral
2015-09-28 Herabstufung ROTH Capital Buy → Neutral
2015-09-09 Eingeleitet Raymond James Strong Buy
2015-05-12 Bestätigt UBS Buy
2015-04-08 Eingeleitet H.C. Wainwright Buy
2015-01-23 Bestätigt ROTH Capital Buy
2014-07-08 Fortgesetzt Oppenheimer Perform
2014-02-11 Eingeleitet Mizuho Buy
Alle ansehen

Verastem Inc Aktie (VSTM) Neueste Nachrichten

pulisher
03:04 AM

Published on: 2025-07-24 00:31:57 - Autocar Professional

03:04 AM
pulisher
02:37 AM

Is Verastem Inc. a good long term investmentConsistent high-yield stocks - Autocar Professional

02:37 AM
pulisher
10:37 AM

High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - The Malaysian Reserve

10:37 AM
pulisher
09:26 AM

High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - Benzinga

09:26 AM
pulisher
09:16 AM

What analysts say about Verastem Inc. stockFree Expert Stock Watchlist - Autocar Professional

09:16 AM
pulisher
06:20 AM

What drives Verastem Inc. stock priceUnmatched profit potential - Autocar Professional

06:20 AM
pulisher
Jul 22, 2025

Verastem Inc. Stock Analysis and ForecastMarket-beating returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

(VSTM) Proactive Strategies - news.stocktradersdaily.com

Jul 22, 2025
pulisher
Jul 18, 2025

Verastem’s Promising KRAS G12D Inhibitor Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Jul 18, 2025
pulisher
Jul 16, 2025

Verastem: The Market Is Ignoring The Progress (NASDAQ:VSTM) - Seeking Alpha

Jul 16, 2025
pulisher
Jul 16, 2025

Why Verastem Inc. stock attracts strong analyst attentionDaily Trade Opportunity - beatles.ru

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Verastem Inc. stock price move sharplyEntry Level Low Risk Picks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Verastem Inc. stock performs during market volatilityFast Moving Stock Alerts - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Avutometinib-Defactinib: A New Standard in Precision Oncology? - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

Verastem’s avutometinib combination shows 31% ORR in ovarian cancer trial - Yahoo Finance

Jul 14, 2025
pulisher
Jul 11, 2025

Verastem Oncology's Breakthrough in LGSOC: A New Standard of Care with Substantial Upside Potential - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Verastem’s cancer drug shows 31% response rate in ovarian cancer trial By Investing.com - Investing.com Canada

Jul 11, 2025
pulisher
Jul 11, 2025

Verastem stock rises after LGSOC treatment data published in medical journal - Investing.com

Jul 11, 2025
pulisher
Jul 11, 2025

Verastem stock rises after LGSOC treatment data published in medical journal By Investing.com - Investing.com South Africa

Jul 11, 2025
pulisher
Jul 11, 2025

Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology - Yahoo Finance

Jul 11, 2025
pulisher
Jul 10, 2025

KRAS Inhibitors Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Target Population, Revenue, Statistics, MOA, ROA and Companies DelveInsight - Barchart.com

Jul 10, 2025
pulisher
Jul 08, 2025

Verastem Oncology's Talent Incentives: Balancing Equity Dilution and Growth - AInvest

Jul 08, 2025
pulisher
Jul 08, 2025

Verastem Oncology announces inducement grants under Nasdaq listing rule - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Verastem Oncology Awards 45,000 Share Options at $4.29 Each to Expand Cancer Drug Development Team - Stock Titan

Jul 08, 2025
pulisher
Jul 04, 2025

Verastem’s Phase 3 Study on Avutometinib and Defactinib: A Potential Game-Changer for Ovarian Cancer Treatment - TipRanks

Jul 04, 2025
pulisher
Jul 02, 2025

Verastem’s Promising Phase 3 Study on Recurrent Ovarian Cancer - TipRanks

Jul 02, 2025
pulisher
Jul 01, 2025

How the (VSTM) price action is used to our Advantage - news.stocktradersdaily.com

Jul 01, 2025
pulisher
Jun 30, 2025

Verastem’s Promising Phase 3 Study on Avutometinib and Defactinib in Ovarian Cancer - TipRanks

Jun 30, 2025
pulisher
Jun 28, 2025

Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World

Jun 28, 2025
pulisher
Jun 26, 2025

Verastem: Approval Secured, Moving On To PDAC And KRAS G12D-Related Cancers - Seeking Alpha

Jun 26, 2025
pulisher
Jun 25, 2025

Verastem (VSTM) Target Price Lowered by RBC Capital | VSTM Stock News - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

RBC Capital Adjusts Target Price for Verastem (VSTM) to $12 | VS - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

RBC Capital Adjusts Target Price for Verastem (VSTM) to $12 | VSTM Stock News - GuruFocus

Jun 25, 2025
pulisher
Jun 25, 2025

Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors - BioSpace

Jun 25, 2025
pulisher
Jun 24, 2025

Verastem Executives Sell Shares to Meet Tax Obligations - TradingView

Jun 24, 2025
pulisher
Jun 20, 2025

Verastem CEO Paterson sells $1.8k in shares By Investing.com - Investing.com UK

Jun 20, 2025

Finanzdaten der Verastem Inc-Aktie (VSTM)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$22.87
price up icon 4.91%
$36.01
price down icon 0.25%
$103.44
price up icon 0.51%
$28.01
price up icon 5.54%
$114.60
price up icon 2.84%
biotechnology ONC
$294.83
price down icon 0.26%
Kapitalisierung:     |  Volumen (24h):